Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer (Adenocarcinoma): early-phase trial registry
13 of 14 indexed Prostate Cancer (Adenocarcinoma) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 13 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Prostate Cancer (Adenocarcinoma): 14 US clinical trials tracked, 13 recruiting.
Prostate Cancer (Adenocarcinoma) is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Shehzad Basaria, M.D., running 1 of these trials.
Enrollment posture brief
Registry condition prostate-cancer-adenocarcinoma
OPEN 13 | RECR 93% | LATE 1 | EARLY 10 | RANK #1230 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Obesity and Obesity-related Medical Conditions (93% recruiting · 14 trials)
Prostate Cancer (Adenocarcinoma) lists 13 open slots (93% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer (Adenocarcinoma) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer (Adenocarcinoma) is recruiting above its size-band peers.
13 of 14 indexed trials (92.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer (Adenocarcinoma) trials is spread across many organizations.
Shehzad Basaria, M.D. accounts for 1 of 14 trials (7.1%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Prostate Cancer (Adenocarcinoma) trials plan to enrol fewer than 100 people.
Median target enrolment is 62 among the 14 trials that report a genuine target (sentinel values excluded). 10 of those (71.4%) plan for fewer than 100 participants.
-
Prostate Cancer (Adenocarcinoma) research is mostly interventional.
13 interventional and 1 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Canadian Cancer Trials Group
NCT06592924
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer Clinical Trials Consortium
NCT06844383
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics
NCT06636682
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
Fox Chase Cancer Center
NCT07219303
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Acerand Therapeutics (Hong Kong) Limited
NCT06801236
PSMA PET for Surveillance After Focal Therapy
University of Chicago
NCT07115914
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Shehzad Basaria, M.D.
NCT06957691
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06616597
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
Massachusetts General Hospital
NCT06862856
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics
NCT07332000
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Halda Therapeutics OpCo
NCT06800313
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
NCT06631521
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
The Methodist Hospital Research Institute
NCT07182279
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
University of Texas Southwestern Medical Center
NCT03525262
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer (Adenocarcinoma) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer (Adenocarcinoma) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer (Adenocarcinoma) page
14 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Prostate Cancer (Adenocarcinoma) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Shehzad Basaria, M.D. sponsors the most Prostate Cancer (Adenocarcinoma) trials on record, review their full trial history before evaluating a specific study. See Shehzad Basaria, M.D.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer (Adenocarcinoma) condition card totals 14 registered trials; most-linked intervention 30Gy (Gray) planning target volume (PTV); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.